According to Vision Research Reports, the multiple sclerosis drugs market size is projected to surpass around US$ 33 billion by 2027.
In terms of revenue, the multiple sclerosis drugs market is anticipated to grow at a CAGR of 6.2% during the forecast period 2020 to 2027.
Rise in prevalence and incidence of multiple sclerosis, rapid increase in the geriatric population leading a surge in cases of multiple sclerosis, and increase in awareness about multiple sclerosis are the major factors fueling the growth of the multiple sclerosis drugs market.
Multiple sclerosis is a central nervous system disorder. It is a potentially disabling disease of the spinal cord and brain. In multiple sclerosis, the immune system attacks the myelin (protective sheath) that shields nerve fibers, which causes communication issues between the brain and the rest of the body. Multiple sclerosis can cause permanent deterioration or damage to the nerves. The cause of multiple sclerosis is still unknown. Researchers believe that genetic and environmental factors contribute to the risk of developing multiple sclerosis.
New Multiple Sclerosis Medication in Research Pipeline Promises Better Results
Although there is no known cure for multiple sclerosis, the adoption of new medications to slow down the progression of multiple sclerosis and manage symptoms is on the rise. In the current scenario, research and development is playing a key role in the development of new treatments. Traditionally, disease-modifying therapies (DMTs) are the main type of medication used to treat multiple sclerosis. Players operating in the multiple sclerosis drugs market are focusing their efforts on gaining approval from the FDA for their newly developed drugs.
In recent times, the FDA has approved a range of disease-modifying therapies to treat different types of multiple sclerosis. Most recently, the FDA approved Fingolimod (Gilenya) to treat pediatric multiple sclerosis and glatiramer acetate injections (Glatopa). While new treatments and medications are receiving FDA approval, several other multiple sclerosis drugs are in the research pipeline and expected to enter the multiple sclerosis drugs market during the forecast period. For instance, a relatively recent phase III clinical trial revealed that siponimod, a potential multiple sclerosis drug, could reduce the relapse rate among individuals suffering from secondary progressive multiple sclerosis. Similarly, the findings from a recent phase II clinical trial suggested that ibudilast could potentially hamper the progression of disability in patients with multiple sclerosis.
Despite the onset of new oral medications, injectable multiple sclerosis drugs are expected to have a higher demand during the forecast period. Thus, in terms of route of administration, the parenteral segment of the multiple sclerosis drugs market is expected to reach a market value of US$ 12.7 Bn in 2020 and hold a market share of 63% in the same year.
Use of Monoclonal Antibodies for Treatment of Multiple Sclerosis
In terms of drug class, the multiple sclerosis drugs market has been segmented into interferon beta, sphingosine 1 phosphate receptor modulators, mixed polymers, NF-κB inhibitor, pyrimidine synthesis inhibitor, monoclonal antibodies, corticosteroids, adrenocorticotropic hormone, and others. The interferon beta segment accounted for a major share of the multiple sclerosis drugs market in 2019. Interferon beta is a cytokine in the interferon family that is used to treat multiple sclerosis. Interferons are proteins produced by the human body. Interferon beta drugs include Avonex, Betaseron, Extavia, Rebif, and Plegridy. However, the monoclonal antibodies segment is expected to dominate the multiple sclerosis drugs market during the forecast period. Dominance of the segment can be attributed to the launch of new monoclonal antibody products for the treatment of multiple sclerosis, including Ofatumumab and Ublituximab, during the forecast period.
High Prevalence of Relapsing-remitting MS (RRMS)
In terms disease type, the multiple sclerosis drugs market has been segmented into relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS), and progressive-relapsing MS (PRMS). The segment is expected to dominate the global market during the forecast period, due to large patient pool with RRMS. About 75% to 85% of population suffering from MS have relapsing-remitting MS (RRMS).
Preference for Parenteral Route of Administration for Drugs
In terms of route of administration, the multiple sclerosis drugs market has been bifurcated into parenteral and oral. The parenteral segment dominated the multiple sclerosis drugs market in terms of share in 2019. The segment is expected to dominate the market during the forecast period. More than 60% of multiple sclerosis drugs are in injectable form. Moreover, launch of injectable drugs, such as Ocrevus, Cladribine, and Ofatumumab, and increase in usage of these drugs for the treatment of multiple sclerosis are likely to drive the segment during the forecast period.
Retail Pharmacies & Drug Stores to be Preferred Distribution Channel
Based on distribution channel, the multiple sclerosis drugs market has been categorized into hospital pharmacies, retail pharmacies & drug stores, and online pharmacies. The retail pharmacies & drug stores segment is projected to constitute significant share of the multiple sclerosis drugs market by 2027. Large share of the segment can be attributed to easy availability of multiple sclerosis drugs at retail pharmacy stores and large number of retail pharmacy stores in the U.S., Europe, and developing countries. Increase in the number of retail pharmacy store chains in developing as well as developed countries is anticipated fuel the growth of the segment during the forecast period.
North America to Create High Incremental Opportunity
In terms of revenue, North America is projected to dominate the multiple sclerosis drugs market from 2020 to 2027. This can be ascribed to higher sales of multiple sclerosis drugs in countries such as the U.S. and Canada. Moreover, rise in prevalence of multiple sclerosis in the region and favorable medical reimbursement policies in the U.S. and Canada drive the market in North America. However, the multiple sclerosis drugs market in Asia Pacific is expected to expand at a relatively high CAGR during the forecast period. The multiple sclerosis drugs market in Asia Pacific is driven by a large pool of patients with multiple sclerosis in China and Japan, approval and launch of new products, and rise in investments by leading players in the region in therapeutic drugs for multiple sclerosis disease.
New product launches in China and Japan and rigorous marketing campaigns adopted by leading players in order to gain competitive advantage are anticipated to augment the market in Asia Pacific during the forecast period. However, patent expiry of top branded drugs in Japan is expected to hamper the growth of the market in the country from 2020 to 2020.
Strategic Collaborations, Investments, and Launch of New Products to Drive Market
The report provides profiles of leading players operating in the multiple sclerosis drugs market. Bayer AG, Teva Pharmaceutical Industries Ltd., Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd., Celgene Corporation, Acorda Therapeutics, Inc., Biogen, Inc., Actelion Pharmaceuticals (Johnson & Johnson), EMD Serono (Merck KGaA), and AbbVie, Inc. are the major players operating in the global multiple sclerosis drugs market. These players have adopted strategies such as strategic collaborations, launch of new products, and investments to increase share and presence in the multiple sclerosis drugs market.
By Drug Class
By Disease Type
By Route of Administration
By Distribution Channel
The Multiple sclerosis drugs market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Multiple sclerosis drugs market for the base year 2019 and the forecast between 2020 and 2027. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Multiple sclerosis drugs market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Multiple sclerosis drugs market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Multiple sclerosis drugs market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Multiple sclerosis drugs capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Multiple sclerosis drugs by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Multiple sclerosis drugs market. These figures have been provided in terms of both revenue and volume for the period 2016 to 2027. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Multiple sclerosis drugs market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Multiple sclerosis drugs market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Multiple sclerosis drugs industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
Multiple sclerosis drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Multiple sclerosis drugs market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Multiple sclerosis drugs market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Multiple sclerosis drugs market. These factors have benefited the growth of the global market for Multiple sclerosis drugs. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Multiple sclerosis drugs. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Multiple sclerosis drugs are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
Audiology Devices Market (By Product: Hearing Aids, Cochlear Implants; By Technology: Digital, Analog; By Sales Channel: Retail, E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030.Read more...
Micro-pumps Market (By Product: Mechanical, Non-mechanical; By Application: Drug Delivery, Medical Devices; By End Use) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030.Read more...
U.S. Behavioral Health Care Software And Services Market (By Component: Software, Support Services; By Delivery Model; By Function; By End Use) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030.Read more...
Medical Imaging Market (By Product: X-ray, CT, MRI, Ultrasound; By End-use: Hospitals, Diagnostic Imaging Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030.Read more...
Medical Imaging Phantoms Market (By Device Type: X-ray, Ultrasound, CT, MRI; By End Use; By Material: Simulating Organs, False Organs) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2022-2030.Read more...